AU2008260399C1 - Vaccine for the prevention of breast cancer relapse - Google Patents

Vaccine for the prevention of breast cancer relapse Download PDF

Info

Publication number
AU2008260399C1
AU2008260399C1 AU2008260399A AU2008260399A AU2008260399C1 AU 2008260399 C1 AU2008260399 C1 AU 2008260399C1 AU 2008260399 A AU2008260399 A AU 2008260399A AU 2008260399 A AU2008260399 A AU 2008260399A AU 2008260399 C1 AU2008260399 C1 AU 2008260399C1
Authority
AU
Australia
Prior art keywords
vaccine
patients
peptide
neu
booster
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008260399A
Other languages
English (en)
Other versions
AU2008260399B2 (en
AU2008260399A8 (en
AU2008260399A1 (en
Inventor
George E. Peoples
Ponniah Sathibalan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Publication of AU2008260399A1 publication Critical patent/AU2008260399A1/en
Publication of AU2008260399A8 publication Critical patent/AU2008260399A8/en
Publication of AU2008260399B2 publication Critical patent/AU2008260399B2/en
Priority to AU2014201488A priority Critical patent/AU2014201488B2/en
Application granted granted Critical
Publication of AU2008260399C1 publication Critical patent/AU2008260399C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/38—Antigens from snakes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2008260399A 2007-06-01 2008-04-11 Vaccine for the prevention of breast cancer relapse Ceased AU2008260399C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014201488A AU2014201488B2 (en) 2007-06-01 2014-03-13 Vaccine for the Prevention of Breast Cancer Relapse

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94152407P 2007-06-01 2007-06-01
US60/941,524 2007-06-01
PCT/US2008/060044 WO2008150577A1 (en) 2007-06-01 2008-04-11 Vaccine for the prevention of breast cancer relapse

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014201488A Division AU2014201488B2 (en) 2007-06-01 2014-03-13 Vaccine for the Prevention of Breast Cancer Relapse

Publications (4)

Publication Number Publication Date
AU2008260399A1 AU2008260399A1 (en) 2008-12-11
AU2008260399A8 AU2008260399A8 (en) 2010-01-07
AU2008260399B2 AU2008260399B2 (en) 2014-01-16
AU2008260399C1 true AU2008260399C1 (en) 2014-07-17

Family

ID=40094045

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008260399A Ceased AU2008260399C1 (en) 2007-06-01 2008-04-11 Vaccine for the prevention of breast cancer relapse

Country Status (16)

Country Link
US (6) US8222214B2 (enExample)
EP (2) EP2722336A1 (enExample)
JP (6) JP5635399B2 (enExample)
KR (5) KR20210097209A (enExample)
CN (2) CN101678093A (enExample)
AU (1) AU2008260399C1 (enExample)
CA (1) CA2687368C (enExample)
CY (1) CY1114912T1 (enExample)
DK (1) DK2162149T3 (enExample)
ES (1) ES2445399T3 (enExample)
HR (1) HRP20140102T1 (enExample)
MX (1) MX2009012858A (enExample)
PL (1) PL2162149T3 (enExample)
PT (1) PT2162149E (enExample)
SI (1) SI2162149T1 (enExample)
WO (1) WO2008150577A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
DK2162149T3 (da) * 2007-06-01 2014-02-10 Jackson H M Found Military Med Vaccine til forebyggelse af brystkræfttilbagefald
ES2639577T3 (es) 2008-12-10 2017-10-27 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vacuna para la prevención de la recurrencia del cáncer de mama
ES2664725T3 (es) 2012-02-17 2018-04-23 Mayo Foundation For Medical Education And Research Métodos y materiales para generar células T CD8+ con la capacidad para reconocer células cancerígenas que expresen un polipéptido HER2/neu
WO2013169538A1 (en) 2012-05-08 2013-11-14 Albert Einstein College Of Medicine Of Yeshiva University Nanoparticle delivery vehicle for s-nitroso-n-acetyl cysteine and uses thereof
CN104736168B (zh) 2012-05-31 2018-09-21 索伦托治疗有限公司 与pd-l1结合的抗原结合蛋白
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
CN103961696A (zh) * 2013-02-05 2014-08-06 日东电工株式会社 经皮给予用疫苗组合物
RU2014102948A (ru) * 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция для мукозального введения
EP2777711A1 (en) 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
CN104513293A (zh) * 2013-09-26 2015-04-15 深圳信立泰药业股份有限公司 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品
US20160258951A1 (en) * 2013-10-28 2016-09-08 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of monitoring immune responses
WO2015127027A1 (en) * 2014-02-20 2015-08-27 Wayne State University Her2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas
CA3013051A1 (en) 2016-01-29 2017-08-03 Heyue Zhou Antigen binding proteins that bind pd-l1
EP3463438B1 (en) * 2016-05-31 2022-04-06 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Vaccine therapy for treatment of endometrial and ovarian cancer
AU2019364258A1 (en) 2018-10-21 2021-06-03 Slsg Limited Llc Combination immunotherapy for treatment of triple-negative breast cancer
KR20240006547A (ko) 2021-05-04 2024-01-15 주식회사 애스톤사이언스 Her2 백신 조성물
KR20230017640A (ko) 2021-07-28 2023-02-06 주식회사 애스톤사이언스 Her2 백신 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121946A9 (en) * 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
US20050202035A1 (en) * 1999-09-30 2005-09-15 Corixa Corporation And Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
CA2055441C (en) * 1989-05-19 2003-01-07 Robert M. Hudziak Her2 extracellular domain
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
FI972514L (fi) * 1994-12-14 1997-08-12 Scripps Research Inst Kasvainspesifisten sytotoksisten T-solujen in vivo aktivointi
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US20030022820A1 (en) * 1995-12-14 2003-01-30 Linda A. Sherman In vivo activation of tumor-specific cytotoxic t cells
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US7060284B1 (en) * 1999-08-03 2006-06-13 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
US20030028907A1 (en) * 2001-07-03 2003-02-06 Walke D. Wade Novel human kielin-like proteins and polynucleotides encoding the same
US20070098776A1 (en) * 1999-12-13 2007-05-03 Fikes John D HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20030224036A1 (en) * 1999-12-13 2003-12-04 Fikes John D Hla class I a2 tumor associated antigen peptides and vaccine compositions
US6602510B1 (en) * 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
EP1417236A4 (en) * 2001-07-10 2010-03-17 Corixa Corp COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ENCAPSULATED PROTEINS AND ADJUVANTS IN MICROSPHERES
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
WO2003076585A2 (en) 2002-03-08 2003-09-18 Board Of Regents, The University Of Texas System Controlled modulation of amino acid side chain length of peptide antigens
KR100555211B1 (ko) * 2002-07-16 2006-03-03 주식회사 팬제노믹스 항암효과를 갖는 Ｈｅｒ-２/ｎｅｕ ＤＮＡ 백신
EP1553966B1 (en) * 2002-10-03 2012-08-01 Wyeth Holdings Corporation Fusion peptides comprising the human papillomavirus e7 and e6 polypeptides and immunogenic compositions thereof
US20070135335A1 (en) 2003-02-10 2007-06-14 Autogen Research Pty Ltd. Therapeutic molecules
US8105615B2 (en) * 2003-06-06 2012-01-31 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2005014634A1 (en) 2003-08-12 2005-02-17 Agt Biosciences Limited A gene and uses therefor
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
US20060275777A1 (en) * 2005-06-03 2006-12-07 Waelti Ernst R Novel strategies for protein vaccines
DK2162149T3 (da) * 2007-06-01 2014-02-10 Jackson H M Found Military Med Vaccine til forebyggelse af brystkræfttilbagefald

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050202035A1 (en) * 1999-09-30 2005-09-15 Corixa Corporation And Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US20040121946A9 (en) * 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DEHQANZADA, Z. A., et al., "Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex® technology," Oncology Reports, 1 March 2007, Vol. 17, No. 3, pages 687-694. *
HUEMAN, M. T., et al., Proceedings of the American Association for Cancer Research Annual Meeting, 2004, Vol. 45, Abstract #1416. *
KHOO, S., et al., "HER2/neu vaccines in breast cancer," Women's Health, 2006, Vol. 2, No. 2, pages 217-223. *
KNUTSON, K. L., et al., "Immunization of Cancer Patients with a HER-2/neu, HLA-A2 Peptide, p369-377, Results in Short-lived Peptide-specific Immunity," Clinical Cancer Research, 2002, Vol. 8, pages 1014-1018. *
MURRAY, J. L., et al., Clinical Cancer Research, 2002, Vol. 8, pages 3407-3418. *
PEOPLES, G. E., et al, Breast Cancer Research and Treatment, 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USE, Abstract 4, Vol. 100, Supplement 1, January 2006, page S6. *
PEOPLES, G. E., et al., "Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients," Journal of Clinical Oncology, 2005, Vol. 23, No. 30, page 7536-7545. *

Also Published As

Publication number Publication date
KR20150106870A (ko) 2015-09-22
AU2008260399B2 (en) 2014-01-16
EP2722336A1 (en) 2014-04-23
JP2017071607A (ja) 2017-04-13
US20220347281A1 (en) 2022-11-03
KR20210097209A (ko) 2021-08-06
PT2162149E (pt) 2014-02-12
US20190060429A1 (en) 2019-02-28
KR20180061412A (ko) 2018-06-07
DK2162149T3 (da) 2014-02-10
JP2014237653A (ja) 2014-12-18
KR102079921B1 (ko) 2020-02-21
KR20200019776A (ko) 2020-02-24
US20130189290A1 (en) 2013-07-25
EP2162149A1 (en) 2010-03-17
KR101572474B1 (ko) 2015-11-30
JP2010529026A (ja) 2010-08-26
US20220241389A1 (en) 2022-08-04
JP2022095926A (ja) 2022-06-28
WO2008150577A1 (en) 2008-12-11
US9370560B2 (en) 2016-06-21
MX2009012858A (es) 2010-02-03
CA2687368A1 (en) 2008-12-11
EP2162149A4 (en) 2012-07-25
US8796220B2 (en) 2014-08-05
CY1114912T1 (el) 2017-01-25
HRP20140102T1 (hr) 2014-03-28
ES2445399T3 (es) 2014-03-03
JP2021001218A (ja) 2021-01-07
US20150182609A1 (en) 2015-07-02
KR101863534B1 (ko) 2018-06-04
AU2008260399A8 (en) 2010-01-07
JP2018199691A (ja) 2018-12-20
CN105816867A (zh) 2016-08-03
KR102283639B1 (ko) 2021-08-02
JP7072467B2 (ja) 2022-05-20
JP5635399B2 (ja) 2014-12-03
US20100209443A1 (en) 2010-08-19
CN101678093A (zh) 2010-03-24
AU2008260399A1 (en) 2008-12-11
JP6097724B2 (ja) 2017-03-15
PL2162149T3 (pl) 2014-04-30
US8222214B2 (en) 2012-07-17
CA2687368C (en) 2018-10-30
KR20100027187A (ko) 2010-03-10
US10842856B2 (en) 2020-11-24
SI2162149T1 (sl) 2014-04-30
EP2162149B1 (en) 2013-11-06

Similar Documents

Publication Publication Date Title
US20220241389A1 (en) Vaccine for the prevention of breast cancer relapse
US9737596B2 (en) Vaccine for the prevention of breast cancer recurrence
AU2014201488B2 (en) Vaccine for the Prevention of Breast Cancer Relapse
HK1196970A (en) Vaccine for the prevention of breast cancer relapse

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE APPLICANT NAME FROM HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. TO THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: DELETE ALL REFERENCE TO 2008260399

TH Corrigenda

Free format text: IN VOL 23, NO 47, PAGE(S) 11301 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC., APPLICATION NO. 2008260399, UNDER INID (71), CORRECT THE APPLICANT NAME TO THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 13 MAR 2014 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 13 MAR 2014

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired